THE US Food and Drug Administration has approved Teva Pharmaceuticals' Cassipa (buprenorphine and naloxone) sublingual film for the maintenance treatment of opioid dependence.
The move provides for a new dosage strength (16mg/4mg) of buprenorphine and naloxone, which is approved in both brand name and generic versions.
"There is an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder," the FDA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Sep 18
